PL2567982T3 - Przeciwciało przeciwko antygenowi rakowo-płodowemu i jego zastosowania - Google Patents

Przeciwciało przeciwko antygenowi rakowo-płodowemu i jego zastosowania

Info

Publication number
PL2567982T3
PL2567982T3 PL11777108T PL11777108T PL2567982T3 PL 2567982 T3 PL2567982 T3 PL 2567982T3 PL 11777108 T PL11777108 T PL 11777108T PL 11777108 T PL11777108 T PL 11777108T PL 2567982 T3 PL2567982 T3 PL 2567982T3
Authority
PL
Poland
Prior art keywords
antibody against
carcinoembryonic antigen
against carcinoembryonic
antigen
antibody
Prior art date
Application number
PL11777108T
Other languages
English (en)
Inventor
Zhihua Yang
Yuliang Ran
Original Assignee
Shanghai Haikang Pharmaceutical Tech.&Deve. Co. Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haikang Pharmaceutical Tech.&Deve. Co. Ltd filed Critical Shanghai Haikang Pharmaceutical Tech.&Deve. Co. Ltd
Publication of PL2567982T3 publication Critical patent/PL2567982T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL11777108T 2010-05-05 2011-03-16 Przeciwciało przeciwko antygenowi rakowo-płodowemu i jego zastosowania PL2567982T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2010101630522A CN101928347B (zh) 2010-05-05 2010-05-05 抗癌胚抗原抗体及其应用
EP11777108.9A EP2567982B1 (en) 2010-05-05 2011-03-16 Antibody against carcinoembryonic antigen and uses thereof
PCT/CN2011/071840 WO2011137687A1 (zh) 2010-05-05 2011-03-16 一种抗癌胚抗原抗体及其应用

Publications (1)

Publication Number Publication Date
PL2567982T3 true PL2567982T3 (pl) 2018-04-30

Family

ID=43367813

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11777108T PL2567982T3 (pl) 2010-05-05 2011-03-16 Przeciwciało przeciwko antygenowi rakowo-płodowemu i jego zastosowania

Country Status (8)

Country Link
US (1) US9056911B2 (pl)
EP (1) EP2567982B1 (pl)
JP (2) JP5987822B2 (pl)
CN (1) CN101928347B (pl)
CA (1) CA2798285C (pl)
ES (1) ES2655998T3 (pl)
PL (1) PL2567982T3 (pl)
WO (1) WO2011137687A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101928347B (zh) * 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
US10656156B2 (en) * 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN104628859A (zh) * 2015-01-26 2015-05-20 佳德资本投资管理（Bvi）有限公司 抗人癌胚抗原抗体及其编码基因和应用
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
WO2018157147A1 (en) * 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
CN110297093B (zh) * 2019-03-18 2022-04-22 山西瑞豪生物科技有限公司 一种检测人免疫球蛋白g4的方法和试剂盒
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024519078A (ja) * 2021-05-21 2024-05-08 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｅａ抗体及びその使用方法
CN114560944B (zh) * 2022-03-30 2022-08-09 北京科跃中楷生物技术有限公司 胶体金颗粒标记的抗体及其应用
CN114409789B (zh) * 2022-03-30 2022-06-07 北京科跃中楷生物技术有限公司 一种胶体金颗粒标记方法及检测试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
CN1216321A (zh) * 1997-10-31 1999-05-12 广州军区广州总医院医务部科训科 癌胚抗原基因启动子dna的克隆方法、序列及其用途
CN1077801C (zh) * 1997-11-19 2002-01-16 中国科学院微生物研究所 癌胚抗原基因工程抗体CL-3-scFv
US20040096826A1 (en) * 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CN1532281A (zh) * 2003-03-21 2004-09-29 吉林大学第一医院 癌胚抗原基因片段的重组及基因疫苗
JP4908440B2 (ja) * 2008-03-06 2012-04-04 株式会社東芝 画像処理装置及び方法
CN101928347B (zh) * 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 抗癌胚抗原抗体及其应用

Also Published As

Publication number Publication date
EP2567982A4 (en) 2013-09-18
EP2567982B1 (en) 2017-11-01
JP5987822B2 (ja) 2016-09-07
CA2798285C (en) 2017-06-06
US20130123471A1 (en) 2013-05-16
CA2798285A1 (en) 2011-11-10
CN101928347B (zh) 2013-03-27
US9056911B2 (en) 2015-06-16
EP2567982A1 (en) 2013-03-13
ES2655998T3 (es) 2018-02-22
WO2011137687A1 (zh) 2011-11-10
CN101928347A (zh) 2010-12-29
JP2016028577A (ja) 2016-03-03
JP2013534406A (ja) 2013-09-05
HK1149937A1 (en) 2011-10-21

Similar Documents

Publication Publication Date Title
PL2567982T3 (pl) Przeciwciało przeciwko antygenowi rakowo-płodowemu i jego zastosowania
IL272831B (en) Meditops and Meditop binding antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
EP2585476A4 (en) ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
PT2946791T (pt) Anticorpos anti-cd277 e suas utilizações
EP2478110A4 (en) CLASS I ANTI-CEA ANTIBODIES AND USES THEREOF
IL232399A0 (en) Anti-2fgfr antibodies and their use
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
PL2510011T3 (pl) Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
ZA201108310B (en) Blocking anti-dkk-1 antibodies and their uses
ZA201302537B (en) Stable and soluble antibodies
SG10201501285RA (en) Anti-alpha2 integrin antibodies and their uses
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2629793A4 (en) CHLAMYDIA ANTIGENE AND ITS USE
AU2011259204A8 (en) Antigen peptide and use thereof
AU2011259204A1 (en) Antigen peptide and use thereof
GB0903151D0 (en) Antibody uses and methods
ZA201407309B (en) Antigens and antigen combinations
GB0906115D0 (en) Antibody and uses thereof
HK1179536A (en) Cd20 antibodies and uses thereof
HK1179169A (en) Anti-ilt5 antibodies and ilt5-binding antibody fragments
GB201207383D0 (en) Antigens and antigen combinations
GB201207385D0 (en) Antigens and antigen combinations
HK1188458A (en) Anti-sod1 antibodies and uses thereof
LT2630159T (lt) Stabilūs ir tirpūs antikūnai